Adalvo and Eurolab strengthen Strategic Partnership in South Africa and SSA Regions
16 October 2023 | Monday | News
Adalvo and Eurolab are pleased to announce the extension of their long-term strategic collaboration, signing a basket deal for three more products to be marketed and distributed in South Africa and as well as certain SSA countries. The current global market size of the products included in this deal exceeded US$ 2BN in 2022, according to IQVIA.
Image Source : Public Domain
These value-added products encompass a diverse range of segments, each catering to specific indications and fulfilling unique patient needs. The portfolio offers a broad list of therapeutic products, some of which include specialty medicine for Pain Relief, Leukaemia, and an exclusive collaboration for Benign Prostatic Hyperplasia (BPH).
With this solid partnership, Eurolab and Adalvo continue to strengthen their position in South Africa and SSA regions, providing patients with high-quality and affordable treatment options.
Anil Okay, CEO of Adalvo, expressed his enthusiasm, saying, "We are proud to continue our partnership with Eurolab, a company that shares our dedication to advancing healthcare solutions. Together, we are poised to make a significant impact in South Africa and SSA regions by providing patients with access to innovative and high-quality treatments."
Lynne du Toit, CEO of Eurolab, echoed this sentiment, stating, "The extension of our collaboration with Adalvo represents a milestone in our journey to improve healthcare across South Africa and SSA countries. By combining our strengths and resources, we aim to meet the diverse healthcare needs of these regions while ensuring affordability and accessibility for all."
Adalvo and Eurolab remain committed to their mission of enhancing healthcare standards and look forward to delivering these value-added products to patients in South Africa and SSA countries.
Anil Okay, CEO of Adalvo, expressed his enthusiasm, saying, "We are proud to continue our partnership with Eurolab, a company that shares our dedication to advancing healthcare solutions. Together, we are poised to make a significant impact in South Africa and SSA regions by providing patients with access to innovative and high-quality treatments."
Lynne du Toit, CEO of Eurolab, echoed this sentiment, stating, "The extension of our collaboration with Adalvo represents a milestone in our journey to improve healthcare across South Africa and SSA countries. By combining our strengths and resources, we aim to meet the diverse healthcare needs of these regions while ensuring affordability and accessibility for all."
Adalvo and Eurolab remain committed to their mission of enhancing healthcare standards and look forward to delivering these value-added products to patients in South Africa and SSA countries.
Most Read
- Biotech and Biopharma Industry Trends: What to Watch for in 2024
- Revolutionizing Drug Discovery: 15 AI Companies to Watch in 2024
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2024
- 2024's Biopharma Roadmap: Top 24 Biopharma Trends to Watch in 2024
- Breakthroughs Unveiled: A Year of Groundbreaking Novel Drug Approvals in 2023
- Revolutionizing Tomorrow: Top 24 Emerging Biotech Innovations to Watch in 2024
Bio Jobs
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
- Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore
- Padraig McDonnell Takes Helm as Agilent Technologies' New CEO, Pledges to Elevate Scientific Impact
- Agilent Singapore and Malaysia Hosts CEO Transition Event: Celebrating Leadership and Welcoming New CEO
- Leica Microsystems Announces Vacancy for Senior Imaging FPGA Testing Engineer in Singapore
- Glen Godresse Takes Helm as CEO of Menarini Asia-Pacific
News
Editor Picks
